SynAct Pharma AB (OSTO:SYNACT) Total Stockholders Equity : kr152.29 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Total Stockholders Equity?

SynAct Pharma AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr152.29 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. SynAct Pharma AB's Book Value per Share for the quarter that ended in Mar. 2024 was kr4.28. The ratio of a company's debt over equity can be used to measure how leveraged this company is. SynAct Pharma AB's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

SynAct Pharma AB Total Stockholders Equity Historical Data

The historical data trend for SynAct Pharma AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Total Stockholders Equity Chart

SynAct Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

12.19

15.87

20.87

126.52

176.19

SynAct Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															268.76	241.50	209.91	176.19	152.29

SynAct Pharma AB (OSTO:SYNACT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

SynAct Pharma AB's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(152.294	-	0)	/	35.571
	=	4.28

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

SynAct Pharma AB's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.474	+	0.024)	/	152.294
	=	0.00

SynAct Pharma AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines